1
|
Salahifar E, Nematollahi D. Electrochemical generation of a Michael acceptor: a green method for the synthesis of 4-amino-3-(phenylsulfonyl)diphenylamine derivatives. NEW J CHEM 2015. [DOI: 10.1039/c5nj00087d] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A green electrochemical method for the synthesis of 4-amino-3-(phenylsulfonyl) diphenylamine derivatives via the reaction of N-phenylquinonediimine with arylsulfinic acids is reported.
Collapse
Affiliation(s)
- Eslam Salahifar
- Faculty of Chemistry
- Bu-Ali-Sina University
- Hamedan 65178-38683
- I. R. Iran
| | | |
Collapse
|
2
|
Walker I, Coleman MD. The blood-brain barrier: In vitro methods and toxicological applications. Toxicol In Vitro 2012; 9:191-204. [PMID: 20650079 DOI: 10.1016/0887-2333(94)00202-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/02/1994] [Indexed: 12/16/2022]
Abstract
The blood-brain barrier (BBB) is reviewed with reference to in vitro cell culture models and their use and potential use in toxicological studies. The structure, function and in vitro study of brain microvessel endothelial cells (BMEC) is briefly described, as well as the effects of a number of xenobiotics, such as solvents, metals, polycations and herbicides, on the viability and barrier function of the BBB model. The biotransformation of xenobiotics is increasingly thought to be responsible for many toxic reactions seen in living systems. Few studies have addressed the effects of the products of biotransformation on the integrity of the barrier model. Many of the specific human bioactivating enzymes, such as cytochrome P-450s, can now be conveniently studied in eukaryotic in vitro gene expression systems. The combination of such systems with a well characterized porcine BMEC culture model might be useful in the study of reactive metabolites on the BBB, in terms of changes in indices of functional and structural BMEC viability. The potential applications and the value of such an experimental approach are discussed.
Collapse
Affiliation(s)
- I Walker
- Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, UK
| | | |
Collapse
|
3
|
Nematollahi D, Amani A. Electrochemical synthesis of the new substituted phenylpiperazines. J Electroanal Chem (Lausanne) 2011. [DOI: 10.1016/j.jelechem.2010.10.024] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Nematollahi D, Esmaili R. A green approach for the electrochemical synthesis of 4-morpholino-2-(arylsulfonyl)benzenamines. Tetrahedron Lett 2010. [DOI: 10.1016/j.tetlet.2010.07.053] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Nematollahi D, Varmaghani F. Paired electrochemical synthesis of new organosulfone derivatives. Electrochim Acta 2008. [DOI: 10.1016/j.electacta.2007.11.066] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Yang XX, Hu ZP, Chan SY, Zhou SF. Monitoring drug-protein interaction. Clin Chim Acta 2005; 365:9-29. [PMID: 16199025 DOI: 10.1016/j.cca.2005.08.021] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2005] [Revised: 08/16/2005] [Accepted: 08/23/2005] [Indexed: 11/25/2022]
Abstract
A variety of therapeutic drugs can undergo biotransformation via Phase I and Phase II enzymes to reactive metabolites that have intrinsic chemical reactivity toward proteins and cause potential organ toxicity. A drug-protein adduct is a protein complex that forms when electrophilic drugs or their reactive metabolite(s) covalently bind to a protein molecule. Formation of such drug-protein adducts eliciting cellular damages and immune responses has been a major hypothesis for the mechanism of toxicity caused by numerous drugs. The monitoring of protein-drug adducts is important in the kinetic and mechanistic studies of drug-protein adducts and establishment of dose-toxicity relationships. The determination of drug-protein adducts can also provide supportive evidence for diagnosis of drug-induced diseases associated with protein-drug adduct formation in patients. The plasma is the most commonly used matrix for monitoring drug-protein adducts due to its convenience and safety. Measurement of circulating antibodies against drug-protein adducts may be used as a useful surrogate marker in the monitoring of drug-protein adducts. The determination of plasma protein adducts and/or relevant antibodies following administration of several drugs including acetaminophen, dapsone, diclofenac and halothane has been conducted in clinical settings for characterizing drug toxicity associated with drug-protein adduct formation. The monitoring of drug-protein adducts often involves multi-step laboratory procedure including sample collection and preliminary preparation, separation to isolate or extract the target compound from a mixture, identification and determination. However, the monitoring of drug-protein adducts is often difficult because of short half-lives of the protein adducts, sampling problem and lack of sensitive analytical techniques for the protein adducts. Currently, chromatographic (e.g. high performance liquid chromatography) and immunological methods (e.g. enzyme-linked immunosorbent assay) are two major techniques used to determine protein adducts of drugs in patients. The present review highlights the importance for clinical monitoring of drug-protein adducts, with an emphasis on methodology and with a further discussion of the application of these techniques to individual drugs and their target proteins.
Collapse
Affiliation(s)
- Xiao-Xia Yang
- Department of Pharmacy, Faculty of Science, National University of Singapore, Science Drive 4, Singapore 117543, Singapore
| | | | | | | |
Collapse
|
7
|
Zhou S, Chan E, Duan W, Huang M, Chen YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 2005; 37:41-213. [PMID: 15747500 DOI: 10.1081/dmr-200028812] [Citation(s) in RCA: 179] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
A number of therapeutic drugs with different structures and mechanisms of action have been reported to undergo metabolic activation by Phase I or Phase II drug-metabolizing enzymes. The bioactivation gives rise to reactive metabolites/intermediates, which readily confer covalent binding to various target proteins by nucleophilic substitution and/or Schiff's base mechanism. These drugs include analgesics (e.g., acetaminophen), antibacterial agents (e.g., sulfonamides and macrolide antibiotics), anticancer drugs (e.g., irinotecan), antiepileptic drugs (e.g., carbamazepine), anti-HIV agents (e.g., ritonavir), antipsychotics (e.g., clozapine), cardiovascular drugs (e.g., procainamide and hydralazine), immunosupressants (e.g., cyclosporine A), inhalational anesthetics (e.g., halothane), nonsteroidal anti-inflammatory drugs (NSAIDSs) (e.g., diclofenac), and steroids and their receptor modulators (e.g., estrogens and tamoxifen). Some herbal and dietary constituents are also bioactivated to reactive metabolites capable of binding covalently and inactivating cytochrome P450s (CYPs). A number of important target proteins of drugs have been identified by mass spectrometric techniques and proteomic approaches. The covalent binding and formation of drug-protein adducts are generally considered to be related to drug toxicity, and selective protein covalent binding by drug metabolites may lead to selective organ toxicity. However, the mechanisms involved in the protein adduct-induced toxicity are largely undefined, although it has been suggested that drug-protein adducts may cause toxicity either through impairing physiological functions of the modified proteins or through immune-mediated mechanisms. In addition, mechanism-based inhibition of CYPs may result in toxic drug-drug interactions. The clinical consequences of drug bioactivation and covalent binding to proteins are unpredictable, depending on many factors that are associated with the administered drugs and patients. Further studies using proteomic and genomic approaches with high throughput capacity are needed to identify the protein targets of reactive drug metabolites, and to elucidate the structure-activity relationships of drug's covalent binding to proteins and their clinical outcomes.
Collapse
Affiliation(s)
- Shufeng Zhou
- Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore.
| | | | | | | | | |
Collapse
|
8
|
Coleman MD, Hadley S, Perris AD, Jorga K, Seydel JK. Studies on the toxicity and efficacy of some ester analogues of dapsone in vitro using rat and human tissues. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2002; 12:7-13. [PMID: 21782618 DOI: 10.1016/s1382-6689(01)00123-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/25/2001] [Revised: 11/22/2001] [Accepted: 11/26/2001] [Indexed: 05/31/2023]
Abstract
The toxicity and efficacy of a series of 13 anti-tubercular sulphone esters has been evaluated using human and rat tissues. The toxicity studies involved comparison of the esters' ability to generate rat microsomally mediated NADPH-dependent methaemoglobin with that of dapsone. All the compounds formed significantly less methaemoglobin in the 1 compartment studies compared with dapsone itself. The ethyl, propyl, 3-methyl-butyl cyclopentyl esters and the carboxy parent derivative all yielded less than 5% of the methaemoglobin generated by dapsone. The 3-nitro benzoic acid ethyl and propyl esters generated 30 and 25% of dapsone's methaemoglobin formation. A similar effect was seen in the 2 compartment system, except for the butyl ester, which yielded similar haemoglobin oxidation to dapsone. The low toxicity ethyl and propyl esters, were also low in toxicity using human liver microsomes, producing less than 30% of the dapsone mediated methaemoglobin. All the compounds except the benzoic acid parent were superior to dapsone in terms of suppression of human neutrophil respiratory burst using a lucigenin-based chemiluminescence assay. The most potent derivatives were the phenyl, propyl and 3-nitro benzoic acid ethyl esters, which were between two- and threefold more potent compared with dapsone in arresting the respiratory burst. Overall, the ethyl ester showed the best combination of low toxicity in the rat and human microsomal systems and its IC(50) was approximately 40% lower than that of dapsone in neutrophil respiratory burst inhibition. These compounds indicate some promise for future development in their superior anti-inflammatory capability and lower toxicity compared with the parent sulphone, dapsone.
Collapse
Affiliation(s)
- Michael D Coleman
- Department of Pharmaceutical Sciences, Mechanisms of Drug Toxicity Group, Aston University, Aston Triangle, Birmingham B4 7ET, UK
| | | | | | | | | |
Collapse
|
9
|
Bence AK, Rogers DT, Worthen DR, Fu M, Littleton JM, Crooks PA. Dapsone analogs as potential polyamine binding site modulators of theN-methyl-D-aspartate receptor complex. Drug Dev Res 2001. [DOI: 10.1002/ddr.8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
10
|
Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin Microbiol Rev 2000; 13:615-50. [PMID: 11023961 PMCID: PMC88953 DOI: 10.1128/cmr.13.4.615] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Professional phagocytes (polymorphonuclear neutrophils and monocytes/macrophages) are a main component of the immune system. These cells are involved in both host defenses and various pathological settings characterized by excessive inflammation. Accordingly, they are key targets for immunomodulatory drugs, among which antibacterial agents are promising candidates. The basic and historical concepts of immunomodulation will first be briefly reviewed. Phagocyte complexity will then be unravelled (at least in terms of what we know about the origin, subsets, ambivalent roles, functional capacities, and transductional pathways of this cell and how to explore them). The core subject of this review will be the many possible interactions between antibacterial agents and phagocytes, classified according to demonstrated or potential clinical relevance (e.g., neutropenia, intracellular accumulation, and modulation of bacterial virulence). A detailed review of direct in vitro effects will be provided for the various antibacterial drug families, followed by a discussion of the clinical relevance of these effects in two particular settings: immune deficiency and inflammatory diseases. The prophylactic and therapeutic use of immunomodulatory antibiotics will be considered before conclusions are drawn about the emerging (optimistic) vision of future therapeutic prospects to deal with largely unknown new diseases and new pathogens by using new agents, new techniques, and a better understanding of the phagocyte in particular and the immune system in general.
Collapse
Affiliation(s)
- M T Labro
- INSERM U 479, Faculté Xavier Bichat, 75018 Paris, France.
| |
Collapse
|
11
|
Coleman MD, Rathbone DL, Endersby CR, Hovey MC, Tims KJ, Lambert PA, Billington DC. Preliminary in vitro toxicological evaluation of a series of 2-pyridylcarboxamidrazone candidate anti-tuberculosis compounds: II(1). ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2000; 8:167-172. [PMID: 10925069 DOI: 10.1016/s1382-6689(00)00037-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
The in vitro toxicity of two amidrazones I [N(1)-(3-benzyloxy-4-methoxybenzylidene)-pyridine-2-carboxamidrazone] and II [N(1)-(4-benzyloxy-3-methoxybenzylidene)-pyridine-2-carboxamidrazone] and their precursors PI (3-benzyloxy-4-methoxybenzaldehyde) and PII (4-benzyloxy-3-methoxybenzaldehyde) was determined using a rat liver metabolism system with human mononuclear leucocytes (MNL) as target cells. The minimum inhibitory concentration for I and II was determined to be between 4 and 8 µg/ml against Mycobacteria fortuitum. In direct contact with human MNL at three concentrations, only II and isoniazid (INH) were significantly more toxic compared with control at 100 and 200 µM. With rat microsomes, INH and PII at 50 µM showed significant toxicity. In the two compartment system without a metabolising system, INH and II were significantly more toxic compared with control and I. In the presence of the metabolising system, INH and PI were more toxic than control and INH was more toxic compared with I. II was not significantly more toxic than control. INH caused more cell death in the presence of the metabolising system compared with its absence. Less toxic compared with INH, compound I has shown promise for future development as an antituberculosis drug.
Collapse
Affiliation(s)
- MD Coleman
- Mechanisms of Drug Toxicity Group, Pharmaceutical Sciences Institute, Aston University, Aston Triangle, B4 7ET, Birmingham, UK
| | | | | | | | | | | | | |
Collapse
|
12
|
Coleman MD, Kuhns MJ. Bioactivation of the cyanide antidote 4-aminopropiophenone (4-PAPP) by human and rat hepatic microsomal enzymes: effect of inhibitors. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 1999; 7:75-80. [PMID: 21781912 DOI: 10.1016/s1382-6689(98)00052-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/1998] [Revised: 12/02/1998] [Accepted: 12/07/1998] [Indexed: 05/31/2023]
Abstract
The bioactivation of the cyanide antidote methaemoglobin former 4-aminopropiophenone (4-PAPP) was studied using rat and human microsomes. With rat liver and NADPH in single and two-compartment systems, dapsone and benzocaine were more potent methaemoglobin generators compared with 4-PAPP. In the single compartment studies, the order of potency of inhibition of 4-PAPP-mediated methaemoglobin formation was cimetidine (1.5 mM)>isoniazid (500 μM)/diethyldithiocarbamate (DDC, 1 mM)>erythromycin (500 μM). Human liver microsomal activation of 4-PAPP in the two-compartment system was partially inhibited by both DDC and cimetidine. These preliminary studies suggest that 4-PAPP may be metabolised by CYP 2C11, 2E1 and 3A in the rat and CYP 2C, 2E1 and probably 3A4 in man.
Collapse
Affiliation(s)
- M D Coleman
- Mechanisms of Drug Toxicity Group, Pharmaceutical Sciences Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK
| | | |
Collapse
|
13
|
Coleman MD, Rathbone DL, Abberley L, Lambert PA, Billington DC. Preliminary in vitro toxicological evaluation of a series of 2-pyridylcarboxamidrazone candidate anti-tuberculosis compounds. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 1999; 7:59-65. [PMID: 21781910 DOI: 10.1016/s1382-6689(98)00055-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/1998] [Revised: 12/02/1998] [Accepted: 12/07/1998] [Indexed: 05/31/2023]
Abstract
We have investigated the toxicity of a series of 2-pyridylcarboxamidrazones in vitro using a rat liver metabolism system as well as human erythrocytes and mononuclear leucocytes (MNL) as target cells. Of the seven derivatives and four precursors tested, only minimal (<2.3%) metabolism-mediated methaemoglobin was formed by two analogues. However, one of these, a naphthylidene 2-pyridylcarboxamidrazone derivative (compound III), was also directly toxic to human MNLs. This toxicity was partially attenuated by the rat metabolising system and incubation of diethyldithiocarbamate or cimetidine together with compound III and the rat metabolising system suppressed the metabolism-dependent detoxification. This indicated that cytochrome P-450-mediated biotransformation of compound III was preventing its direct toxicity to the MNL. Of the seven derivatives tested, six were low in toxicity to MNL directly and in the presence of a metabolising system. The two compounds which were the most potent anti-mycobacterially, the dimethylpropyl and dimethylethyl benzylidene amidrazone derivatives, were also the least toxic to MNL and erythrocytes. This amidrazone series has shown promise for future development as antituberculosis drugs.
Collapse
Affiliation(s)
- M D Coleman
- Mechanisms of Drug Toxicity Group, Pharmaceutical Sciences Institute, Aston University, Aston Triangle, Birmingham, B4 7ET, UK
| | | | | | | | | |
Collapse
|
14
|
Coleman MD, Taylor CH. Bioactivation of benzocaine to a methaemoglobin-forming metabolite by rat and human microsomes in vitro. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 1997; 3:47-52. [PMID: 21781757 DOI: 10.1016/s1382-6689(96)00138-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/1996] [Revised: 10/16/1996] [Accepted: 11/01/1996] [Indexed: 05/31/2023]
Abstract
Benzocaine-mediated methaemoglobin-generation was compared with that of dapsone in vitro. Direct incubation of benzocaine with washed human erythrocytes alone at up to 15 mM did not result in significant methaemoglobin formation (0.4 ± 0.1%). With rat microsomes, dapsone-dependent methaemoglobin formation was almost two-fold that of benzocaine at 30 min (56.5 ± 0.7% vs 31.6 ± 2.4% P < 0.005)). Benzocaine-mediated methaemoglobin formation was significantly reduced in the presence of DDC (diethyldithiocarbamate) at the 10 (P < 0.005) and 20 (P < 0.025) min time points. At 30 min, cimetidine reduced benzocaine-mediated methaemoglobin from 34.4 ± 8.7% to less than 3% (P < 0.005). The methaemoglobin forming capacity of dapsone was significantly inhibited at all three time points by both DDC (P < 0.005) and cimetidine (P < 0.005). Incubation of benzocaine with microsomes from five human livers showed that each liver produced methaemoglobin-forming metabolites. No inhibitory effect was seen with DDC, although cimetidine caused a significant reduction (32.8 ± 12.4% overall) in benzocaine-mediated methaemoglobin formation in the four livers tested.
Collapse
Affiliation(s)
- M D Coleman
- Mechanisms of Drug Toxicity Group, Department of Pharmaceutical Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
| | | |
Collapse
|
15
|
Coleman MD, Thorpe S, Lewis S, Buck NS, Perris AD, Seydel JK. Preliminary evaluation of the toxicity and efficacy of novel 2,4-diamino-5-benzylpyrimidine-sulphone derivatives using rat and human tissues in vitro. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 1996; 2:389-395. [PMID: 21781747 DOI: 10.1016/s1382-6689(96)00076-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/16/1996] [Revised: 07/12/1996] [Accepted: 08/22/1996] [Indexed: 05/31/2023]
Abstract
Four novel combined dapsone and trimethoprim analogues, K-120, K-150, K-138 and DRS-506, have been compared with dapsone in their methaemoglobin forming abilities as well as their anti-inflammatory properties using rat and human tissues in vitro. All four compounds formed consistently less methaemoglobin compared with dapsone in both the rat and human microsomes. Using human microsomes from five livers, K-120 was significantly less toxic than the other analogues in three of the five livers (P < 0.01). DRS-506 and K-138 both inhibited the human neutrophil respiratory burst to a significantly greater degree compared with dapsone at 0.5 mM (P < 0.01), while K-120 and K-150 showed no significant effect at 0.5 mM. At 1 mM, DRS-506, K-120 and K-138 were more potent than dapsone (P < 0.01), although K-150 appeared to increase the neutrophil activation. All four analogues caused a significant reduction in neutrophil adhesion to human umbilical vein cells at 0.1 mM. In view of its efficacy and low toxicity, K-120 shows considerable promise for future clinical evaluation.
Collapse
Affiliation(s)
- M D Coleman
- Mechanisms of Drug Toxicity Group, Department of Pharmaceutical Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
| | | | | | | | | | | |
Collapse
|
16
|
Ahmadi M, Khalaf LF, Smith HJ, Nicholls PJ. A dapsone-induced blood dyscrasia in the mouse: evidence for the role of an active metabolite. J Pharm Pharmacol 1996; 48:228-32. [PMID: 8935178 DOI: 10.1111/j.2042-7158.1996.tb07129.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
In the female mouse, dapsone (50-500 mg kg-1, p.o.) caused a dose-related methaemoglobinaemia which peaked at 0.5-1 h with recovery to baseline values occurring by 4 h. Cimetidine (100 mg kg-1, p.o.), a known inhibitor of several hepatic P450 isozymes administered 1 h before dapsone, prevented the methaemoglobinaemia. In-vitro, dapsone required activation by mouse hepatic microsomes to cause methaemoglobin formation in mouse erythrocytes and cytotoxicity to human mononuclear leucocytes. In both instances, the toxic effects were markedly reduced by cimetidine. Daily dosing of mice with dapsone (50 mg kg-1, p.o.) for 3 weeks induced a blood dyscrasia, characterized by a fall of platelet and white blood cell counts, which was inhibited by cimetidine (100 mg kg-1, p.o. daily). It is concluded that an active metabolite of dapsone arising from a P450-dependent pathway is involved in the genesis not only of the methaemoglobinaemia but also the blood dyscrasia arising from repeated administration of the drug in this species.
Collapse
Affiliation(s)
- M Ahmadi
- Welsh School of Pharmacy, UWCC, Cardiff, UK
| | | | | | | |
Collapse
|
17
|
Abstract
1. Dapsone is a potent anti-inflammatory and anti-parasitic compound, which is metabolised by cytochrome P-450 to hydroxylamines, which in turn cause methaemoglobinaemia and haemolysis. However, during the process of methaemoglobin formation, erythrocytes are capable of detoxifying the hydroxylamine to the parent drug, which may either reach the tissues to exert a therapeutic effect or return to the liver and be re-oxidised in a form of systemic cycling. This glutathione-dependent effect, combined with the un-ionised state of the drug at physiological pH, may contribute to its efficacy. 2. Paradoxically, other aspects of the glutathione-dependent cycling of the hydroxylamine metabolite may contribute to the major adverse reaction of the drug, agranulocytosis. Erythrocytes exposed to the metabolite and repeatedly washed may still release the hydroxylamine in sufficient concentration to kill mononuclear leucocytes in vitro. Thus, erythrocytes may be a conduit for the hydroxylamine to reach the bone marrow to covalently bind to granulocyte precursors, which may trigger an immune response in certain individuals and may lead to the potentially fatal eradication of granulocytes from the circulation. 3. Attempts to increase patient tolerance to dapsone have been most successful using a metabolic inhibitor to reduce hepatic oxidation of the drug to the hydroxylamine. Methaemoglobin formation in the presence of cimetidine was maintained at 30% below control levels for almost 3 mo, and patients' reported side effects such as headache and lethargy were significantly reduced. 4. As clinical application of new and safer dapsone analogues is years away, the use of cimetidine provides an immediate route to increasing patient compliance during dapsone therapy, especially in those maintained on dapsone dosages in excess of 200 mg/day.
Collapse
Affiliation(s)
- M D Coleman
- Department of Pharmaceutical Sciences, Aston University, Birmingham, UK
| |
Collapse
|
18
|
Coleman MD, Rhodes LE, Scott AK, Verbov JL, Friedmann PS, Breckenridge AM, Park BK. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br J Clin Pharmacol 1992; 34:244-9. [PMID: 1389948 PMCID: PMC1381395 DOI: 10.1111/j.1365-2125.1992.tb04131.x] [Citation(s) in RCA: 82] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
1. We have attempted to reduce dapsone-dependent methaemoglobinaemia formation in six dermatitis herpetiformis patients stabilised on dapsone by the co-administration of cimetidine. 2. In comparison with control, i.e. dapsone alone, methaemoglobinaemia due to dapsone fell by 27.3 +/- 6.7% and 26.6 +/- 5.6% the first and second weeks after commencement of cimetidine administration. The normally cyanotic appearance of the patient on the highest dose of dapsone (350 mg day-1), underwent marked improvement. 3. There was a significant increase in the trough plasma concentration of dapsone (2.8 +/- 0.8 x 10(-5)% dose ml-1) at day 21 in the presence of cimetidine compared with control (day 7, 1.9 +/- 0.6 x 10(-5)% dose ml-1, P less than 0.01). During the period of the study, dapsone-mediated control of the dermatitis herpetiformis in all six patients was unchanged. 4. Trough plasma concentrations of monoacetyl dapsone were significantly increased (P less than 0.05) at day 21 (1.9 +/- 1.0 x 10(-5)% dose ml-1) compared with day 7 (1.6 +/- 0.9 x 10(-5)% dose ml-1:control). 5. Over a 12 h period, 20.6 +/- 8.9% (day 0) of a dose of dapsone was detectable in urine as dapsone hydroxylamine. Significantly less dapsone hydroxylamine was recovered from urine at day 14 (15.0 +/- 8.4) in the presence of cimetidine, compared with day 0 (control: P less than 0.05). 6. The co-administration of cimetidine may be of value in increasing patient tolerance to dapsone, a widely used, effective, but comparatively toxic drug.
Collapse
Affiliation(s)
- M D Coleman
- Department of Pharmacology and Therapeutics, Liverpool
| | | | | | | | | | | | | |
Collapse
|